These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24652317)

  • 41. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma.
    Wellenreuther R; Kraus JA; Lenartz D; Menon AG; Schramm J; Louis DN; Ramesh V; Gusella JF; Wiestler OD; von Deimling A
    Am J Pathol; 1995 Apr; 146(4):827-32. PubMed ID: 7717450
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Primary ectopic intraosseous meningioma associated with multiple meningioma in a patient with central neurofibromatosis].
    Poptodorov G; Gabrovski S; Kamenova M; Nacheva M; Iordanov I; Shirov T; Petkov R; Dŭbov D
    Khirurgiia (Sofiia); 2006; (4-5):64-7. PubMed ID: 18843923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Aberrant methylation of NF2, TIMP-3 and THBS1 genes and their diagnostic values in meningiomas].
    Gong J; Zhu SG; Wu CY; Li XG; Liu YG; Ren XH; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2889-92. PubMed ID: 23328233
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mouse models of neurofibromatosis 1 and 2.
    Gutmann DH; Giovannini M
    Neoplasia; 2002; 4(4):279-90. PubMed ID: 12082543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular genetics of meningiomas.
    Ng HK
    Asian J Surg; 2005 Jan; 28(1):11-2. PubMed ID: 15691790
    [No Abstract]   [Full Text] [Related]  

  • 46. Multifocality in neurofibromatosis type 2.
    Evans DG; Stivaros SM
    Neuro Oncol; 2015 Apr; 17(4):481-2. PubMed ID: 25537020
    [No Abstract]   [Full Text] [Related]  

  • 47. Neurofibromatosis type 2.
    Thomas G; Mérel P; Sanson M; Hoang-Xuan K; Zucman J; Desmaze C; Melot T; Aurias A; Delattre O
    Eur J Cancer; 1994; 30A(13):1981-7. PubMed ID: 7734211
    [No Abstract]   [Full Text] [Related]  

  • 48. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
    Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
    Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors.
    Kluwe L; Friedrich RE; Hagel C; Lindenau M; Mautner VF
    J Invest Dermatol; 2000 May; 114(5):1017-21. PubMed ID: 10771486
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.
    Ruttledge MH; Sarrazin J; Rangaratnam S; Phelan CM; Twist E; Merel P; Delattre O; Thomas G; Nordenskjöld M; Collins VP
    Nat Genet; 1994 Feb; 6(2):180-4. PubMed ID: 8162072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.
    Wellenreuther R; Waha A; Vogel Y; Lenartz D; Schramm J; Wiestler OD; von Deimling A
    Lab Invest; 1997 Dec; 77(6):601-6. PubMed ID: 9426397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NF2 gene analysis distinguishes hemangiopericytoma from meningioma.
    Joseph JT; Lisle DK; Jacoby LB; Paulus W; Barone R; Cohen ML; Roggendorf WH; Bruner JM; Gusella JF; Louis DN
    Am J Pathol; 1995 Nov; 147(5):1450-5. PubMed ID: 7485407
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A new tumor suppressor gene responsible for type 2 neurofibromatosis is inactivated in neurinoma and meningioma].
    Sanson M
    Rev Neurol (Paris); 1996 Jan; 152(1):1-10. PubMed ID: 8729390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical course and management of intracranial meningiomas in neurofibromatosis type 2 patients.
    Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A
    Neurol Neurochir Pol; 2015; 49(6):367-72. PubMed ID: 26652870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2.
    Fisher LM; Doherty JK; Lev MH; Slattery WH
    Otol Neurotol; 2007 Dec; 28(8):1083-90. PubMed ID: 18043434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene?
    Bruder CE; Ichimura K; Blennow E; Ikeuchi T; Yamaguchi T; Yuasa Y; Collins VP; Dumanski JP
    Genes Chromosomes Cancer; 1999 Jun; 25(2):184-90. PubMed ID: 10338003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiplex ligation-dependent probe amplification (MLPA) screening in meningioma.
    Martínez-Glez V; Franco-Hernández C; Lomas J; Peña-Granero C; de Campos JM; Isla A; Rey JA
    Cancer Genet Cytogenet; 2007 Mar; 173(2):170-2. PubMed ID: 17321335
    [No Abstract]   [Full Text] [Related]  

  • 59. Neurofibromatosis type 2: Multiple intra-dermal tumors in a toddler.
    Rustad CF; Dahl HM; Bowers NL; Sitek JC; Heiberg A; Huson S; Prescott T; Evans DGR
    Am J Med Genet A; 2017 May; 173(5):1447-1449. PubMed ID: 28371307
    [No Abstract]   [Full Text] [Related]  

  • 60. Neurofibromatosis type 2 in an infant presenting with visual impairment confirmed by genetic mutation analysis.
    Kim JE; Ruttum MS
    Retina; 2005; 25(7):938-40. PubMed ID: 16205576
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.